Antibody engagement with amyloid‐beta does not inhibit [11C]PiB binding for PET imaging

• Published in: Journal of neurochemistry Vol. 168; no. 9; pp. 2601 - 2610
• Main Authors: Xiong, Mengfei, Dahlén, Amelia, Roshanbin, Sahar, Wik, Elin, Aguilar, Ximena, Eriksson, Jonas, Sehlin, Dag, Syvänen, Stina
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.09.2024
• Subjects: [11C]PiB; Aggregates; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - metabolism; Alzheimer's disease; Alzheimer's disease (AD); Amyloid beta-Peptides - immunology; Amyloid beta-Peptides - metabolism; amyloid PET; amyloid‐beta; Aniline Compounds - pharmacology; Animals; Antibodies; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal, Humanized - pharmacology; antibody treatment; Autoradiography; Benzothiazoles - pharmacology; Binding; Brain; Brain - diagnostic imaging; Brain - drug effects; Brain - metabolism; Carbon Radioisotopes; Cognitive ability; Female; Health services; Humans; immunotherapy; Male; Medical imaging; Mice; Mice, Transgenic; Monoclonal antibodies; Myeloid cells; Neurodegenerative diseases; Neuroimaging; Patients; Plaque, Amyloid - diagnostic imaging; Plaque, Amyloid - metabolism; Positron emission; Positron emission tomography; Positron-Emission Tomography - methods; Radiopharmaceuticals; Senile plaques; Thiazoles - pharmacology; β-Amyloid; [11C]PiB; Alzheimer's disease (AD); antibody treatment; immunotherapy; amyloid PET; amyloid‐beta

The elimination of amyloid‐beta (Aβ) plaques in Alzheimer's disease patients after treatment with anti‐Aβ antibodies such as lecanemab and aducanumab is supported by a substantially decreased signal in amyloid positron emission tomography (PET) imaging. However, this decreased PET signal has no...